^
Association details:
| Biomarker: | CDKN2B deletion |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
IMPACT OF TP53 AND RECURRENT SOMATIC MUTATIONS ON THE OUTCOMES OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T)
Published date:
05/12/2021
Excerpt:
This is a single center experience of R/R DLBCL patients treated with CAR-T...The 3-month progression rate was 2/7 (29%) for TP53mut and 6/8 (75%) for TP53wt with significantly higher PFS probability in TP53mut patients (p = 0.002). The 3-month progression rates for CDKN2A/B loss and wild-type were 5/5 (100%) and 3/10 (30%) respectively with lower PFS probability in patients with CDKN2A/B loss (p<0.001).
